
Secondary acute myeloid leukemia (sAML), arising from prior hematologic disease or genotoxic therapy, historically carries a worse prognosis than de novo AML. Diagnosing sAML relies on the history of blood count abnormalities without known antecedent disease. While abnormal counts' impact on outcomes is uncertain, recent guidelines include secondary mutations as high-risk factors. In a study of 734 patients, abnormal counts didn't predict prognosis after genetic adjustment in de novo AML. Prior disease or therapy didn't heighten death risk compared to de novo, implying genetics, per 2022 guidelines, dictates prognostic impact. Genetics should guide AML risk assessment and clinical trial selection.
Like
Save
Share